New opportunity to induce remission of peanut allergy in young children through oral immunotherapy

A clinical trial funded by the National Institutes of Health found that giving a peanut immunotherapy to children with severe peanut allergies between the ages of 1 and 3 years safely removes allergies to mostly peanuts and induces remission of peanut allergies in five. Immunotherapy consisted of a daily oral dose of peanut flour for … Read more

Ketamine plus psychological therapy can help people stay off alcohol for longer time

People with severe alcohol use disorder were able to stay off alcohol for longer when treated with low doses of ketamine with psychotherapy in a clinical trial. The University of Exeter led the Ketamine Alcohol Relapse Reduction Trial (KARE) and was funded by the Medical Research Council. The phase two trial is the first of … Read more

Phase 1 clinical trial shows the safety, feasibility of CAR-M cell therapy for solid tumors

Preliminary results from Penn Medicine in an ongoing first-ever human clinical trial examining the safety, tolerability, and feasibility of macrophage chimeric antigen (CAR-M) have helped demonstrate the feasibility of this innovative immunotherapy, which advances the scientific groundbreaking discovery of CAR T-cell therapy. In Penn- for Solid Cancer Tumors and presents a promising new strategy in … Read more

Clinical trial shows preliminary efficacy of all-oral regimen for patients with lenalidomide-refractory multiple myeloma

Early results from the Clinical Trials Alliance in Oncology randomized clinical trials of adults with relapsing multiple myeloma in frontline treatment of lenalidomide show that adding ixazomib (Ninlaro®) to pomalidomide and dexamethasone as part of second-line treatment prolonged the time patients lived before being treated. . Exacerbation of disease (progression-free survival) compared to patients who … Read more

Ad5-nCoV vaccine safe and effective against symptomatic, severe COVID-19, trials shows

Single dose of Ad5-nCoV (Convidecia), a COVID-19 vaccine developed in China, is 57.5% effective against symptoms of COVID-19 and 91.7% effective against severe COVID-19 disease onset 28 days after vaccination, according to a randomized phase 3 Censored trial published in scalpel. The report indicates that Ad5-nCoV is safe, with no serious vaccine-related adverse events or … Read more

Single-patient pilot study shows the ability of antisense oligonucleotide to suppress mutant ALS gene

Using a synthetic short chain of chemically modified nucleotides engineered at the Institute of RNA Therapeutics at UMass Chan School of Medicine, Robert H. The ALS gene known as C9ORF72 in a pilot study of a single patient. C9ORF72 is the most common cause of familial amyotrophic lateral sclerosis (ALS) and familial frontotemporal dementia (FTD). … Read more

Wistar announces initiation of Phase 2 clinical study of VK-2019 in patients with advanced head and neck cancer

The Wistar Institute announces the start of a phase II clinical study of VK-2019 in patients with advanced Epstein-Barr Carcinoma (EBV)-nasopharyngeal carcinoma (NPC) and lymphoma. The study, which is being led by researchers at Stanford University School of Medicine, will include patients who have recurred, progressed after standard treatment, or who have not responded to … Read more

LIVE-AIR trial demonstrates efficacy of Lenzilumab for treatment of COVID patients with decreased oxygen saturation

The novel coronavirus 2019 (COVID-19) pandemic was caused by a new coronavirus, i.e., severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The RNA virus causes mild to severe symptoms and has a high transmission rate. In severe infection, patients often have a highly inflammatory response, which has been associated with morbidity and mortality due to COVID-19 disease. … Read more